PacBio and Covaris Unveil Workflow for HiFi Long-Read Sequencing of FFPE Tumor Samples, Boosting Cancer Research
Summary
PacBio and Covaris have announced a new joint workflow that enables high-fidelity (HiFi) long-read sequencing of formalin-fixed, paraffin-embedded (FFPE) tumor samples, a significant advancement for cancer research. This integrated solution combines Covaris' truXTRAC FFPE extraction with PacBio's Kinnex library preparation and Revio system, overcoming historical challenges of DNA damage in FFPE samples. This development is particularly important for PacBio, which recently reported a substantial net loss as it pivots its technology focus. The workflow demonstrates superior detection of structural variants and direct phasing of mutations compared to traditional short-read sequencing, unlocking vast archives of clinically relevant samples for comprehensive genomic profiling. Traders should monitor the adoption of this workflow and its potential to drive sales of PacBio's sequencing platforms, especially after its formal presentation at the upcoming AACR Annual Meeting.
At the time of this announcement, PACB was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $474.1M. The 52-week trading range was $0.85 to $2.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.